The FDA has finalized its first dedicated guidance for companies testing psychedelic drugs in humans, and for efficacy trials the central message is methodological: sponsors must show that a psychedelic works, not merely that participants who recognize they received the active drug report feeling better. The guidance, “Psychedelic Drugs: Considerations for Clinical Investigations,” was published in the Federal Register on July 14, 2026, finalizing a draft first circulated in 2023. It covers classic psychedelics such as psilocybin and LSD, which primarily act through the 5-HT2A serotonin receptor, as well as entactogens such as MDMA and other drugs that produce related alterations in perception and consciousness.
The document spans chemistry, manufacturing, toxicology, abuse potential, trial design, and safety monitoring. It is explicitly nonbinding and creates no shortcut: psychedelic programs face the same evidentiary standard for approval as any other drug.
The problem at the center of the trial-design section
Psychedelics strain the standard drug trial. The gold-standard design is double-blind and placebo-controlled, but the intense perceptual and emotional effects of a psychedelic can make treatment allocation difficult to conceal. The FDA has a formal term for the result: “functional unblinding.” Participants, therapists, monitors, or raters may infer who received the active compound, and that knowledge can shape what they expect, observe, and report.
The extent of the problem is well documented. In a systematic review by Nayak and colleagues, 81 of 86 psychedelic trials (94%) reported using blinding, but only 14 assessed blind integrity at all — and only eight of those checked whether participants themselves remained blinded. When patients on the drug expect to improve and those on placebo expect nothing, a trial can no longer cleanly separate the drug’s effect from the expectation of benefit. Functional unblinding and expectancy bias were among several concerns raised during the FDA’s review of Lykos Therapeutics’ MDMA-assisted therapy for PTSD in 2024, alongside questions about safety reporting, therapist conduct, and the contribution of psychotherapy.
What the FDA is asking for
Rather than one mandate, the guidance offers a menu of countermeasures. Sponsors are encouraged to consider alternatives to inert placebos — including lower doses of the psychedelic itself, or other psychoactive controls that reproduce some aspects of the experience — and to use questionnaires measuring both whether unblinding occurred and what participants expected before randomization and after treatment. Most notably, the FDA suggests that complementary trials could be paired: a placebo-controlled study alongside a separate dose-response trial comparing low, medium, and high doses without placebo, the latter carrying less risk of functional unblinding while helping characterize the dose-response relationship. It also asks sponsors to separate the drug’s effect from the structured psychotherapy most programs wrap around it, noting that the therapy component’s independent contribution “has not been characterized.”
On safety, the guidance calls for two monitors to remain present throughout each dosing session, with an on-call physician able to reach the site within 15 minutes if the lead monitor is not a physician. For compounds with activity at the 5-HT2B receptor that are intended for chronic administration, it recommends baseline and follow-up echocardiograms because that receptor has been associated with heart-valve damage, though the FDA notes the relevance to the intermittent dosing expected for many psychedelics remains uncertain.
Why it matters now
The timing isn’t incidental. Compass Pathways says two Phase 3 trials of its synthetic psilocybin candidate, COMP360, have met their primary endpoints in treatment-resistant depression; a rolling NDA submission and initial FDA review are already underway, with the company expecting to complete the submission in the fourth quarter of 2026. Alongside a public hearing the FDA has scheduled for September 14 — seeking input on the potential therapeutic use of psychedelics in supervised, supportive settings — the guidance signals an agency preparing for decisions it expects to make.
For a field that has run on striking early results and considerable enthusiasm, the through-line is sobering and arguably overdue: extraordinary subjective effects are not the same as proven efficacy, and the FDA has now made explicit how sponsors are expected to design trials capable of telling the two apart.
Sources
- FDA final guidance, “Psychedelic Drugs: Considerations for Clinical Investigations”
- Federal Register notice, July 14, 2026 (91 FR 43101)
- Nayak et al., “Control Conditions in Randomized Trials of Psychedelics: An ACTTION Systematic Review”, Journal of Clinical Psychiatry, 2023
- Compass Pathways, Phase 3 COMP006 26-week data and NDA update, July 7, 2026
This is a developing regulatory story; details of individual drug-development programs may change as trials and FDA review proceed.
